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Abstract
Background: The incidence of herpes zoster (HZ) is increasing and poses a significant health concern to aging
populations. Several studies suggest an increased risk of stroke following zoster infection, but the results are conflicting.
We conducted a systematic review and meta-analysis to determine if stroke risk is increased following HZ infection.
Methods: A search of MEDLINE, EMBASE, Google scholar, Web of Science, CAB Direct, Cumulative Index to Nursing and
Allied Health Literature, and Evidence Based Medicine Reviews was conducted for observational studies of adults with HZ
infection that examined stroke and TIA risk from January 1, 1966 to May 31, 2016. Adjusted relative risks reported for
similar follow-up durations were pooled across studies separately using random-effects inverse variance models.
Results: Data were pooled from nine studies. Relative risk for stroke after zoster was 1.78 (95% CI 1.70–1.88) for the first
month following herpes zoster, dropping progressively to 1.43 (95% CI 1.38–1.47) after 3 months, to 1.20 (95% CI 1.14–1.
26) after 1 year. We found that stroke risk increases by a larger margin during the first month after a herpes zoster
ophthalmicus episode: relative risk 2.05 (95% CI 1.82–2.31). The risk remains elevated one year after the acute episode.
Conclusions: Herpes zoster is an established risk factor for increasing the risk of stroke, especially shortly after infection.
Vaccination should be encouraged in patients at high risk of cardiovascular disease.
Keywords: Herpes zoster, Meta-analysis, Stroke, Transient ischemic attacks, TIA, Aging
Background
Varicella zoster virus (VZV) is a member of the herpes
virus family with the characteristic capacity to persist in
the body after primary infection and cause latent infec-
tion with the risk of reactivation [1]. Primary infection
with varicella, also known as chickenpox, is a contagious
but a relatively harmless disease that typically affects
susceptible children, although it can affect naïve adults
as a more severe condition [2, 3]. Viremia during pri-
mary infection allows VZV to seed the cranial-nerves or
dorsal-root ganglia and lie dormant until reactivation
[1]. Reactivation and secondary VZV infection typically
occurs in older individuals, perhaps due to compromise
of the immune system through medical conditions or
medications, and results in herpes zoster (HZ) infection,
commonly known as shingles [4]. In VZV reactivation,
the virus multiplies and migrates along the nerve to the
corresponding dermatome. Postherpetic neuralgia, or
pain persisting for 90 days or more after rash starts, is
the most common complication of HZ [5, 6]. Because of
its reactivation within the nervous system, HZ can cause
many other neurological complications including ophthal-
micus, a life threatening condition which frequently
requires hospitalization and antiviral treatment [7, 8].
Ramsay Hunt syndrome, meningitis, encephalitis, and
transverse myelitis are also rare neurologic complications
of zoster [7, 9, 10]. Recently, investigators have published
several reports on patients with zoster being at higher risk
for ischemic or hemorrhagic strokes, however some stud-
ies do not find long-term associations and disagree over
the time period at which zoster patients remain at risk of
stroke outcomes [11]. With over 90% of individuals in the
United States showing serological evidence of exposure to
VZV and because one in 3 individuals will experience zos-
ter over their lifetime, [4] the potential for HZ reactivation
to increase the risk of stroke is a relevant health concern
in today’s society. The overall objective of our paper was
to conduct a systematic review and pool the results of the
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studies evaluating stroke risk following an acute episode
of herpes zoster.
Methods
This systematic review and meta-analysis was reported
according to the MOOSE guidelines for the reporting of
observational studies [12].
Data sources and search strategy
We conducted a search of MEDLINE EMBASE, Google
scholar, Web of Science, CAB Direct, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), and Evi-
dence Based Medicine Reviews (EBM) for articles reporting
on herpes zoster infection and stroke risk from January 1,
1966 to May 31, 2016. EBM is a collection of seven differ-
ent libraries including the American College of Physicians
journal club, Cochrane Central, Cochrane Systematic Re-
views, Cochrane Methodology, Database of Abstracts of
Reviews of Effectiveness, Health Technology Assessments,
and National Health Services Economic Evaluation Data-
base. Search terms as keywords, Mesh terms and subject
headings included: varicella OR zoster OR herpe* OR post-
herpe* OR herpes ophthalmicus OR VZV OR shingle* AND
stroke OR TIA OR transient ischemic attack OR brain
ischemia OR cerebrovascular or cerebral ischemia. After
pooling the articles and deleting duplicates, a manual
review of titles was conducted screening for relevant topics
and keywords. Another final manual review of article ab-
stracts was conducted on shortlisted articles. If the article
was a published abstract in a journal, it was captured in our
search. The literature search was performed by two authors
(JR and FM) and customized for each database with the
help of a university librarian. Uncertainty and revisions
were resolved by consensus.
Inclusion and exclusion criteria
We included all English studies which evaluated either
stroke or transient ischemic attacks (TIA) in humans
18 years of age or older following an acute episode of
herpes zoster or herpes zoster ophthalmicus (HZO). We
excluded cases and case series reports, and literature re-
views. For published abstracts found, we contacted the
authors to obtain the full manuscript, but if unavailable,
we excluded the study.
Data extraction study verification and quality assessment
Data was extracted independently by two authors (FM
and JR) using a standardized abstraction form. Discrep-
ancies were resolved through discussion with another
author (KR). Data extracted from the studies included
the author, date of the study, type of study, inclusion
and exclusion criteria, number of patients, HZ defin-
ition, follow up period, confounders adjusted for, demo-
graphics and study outcome data.
Two authors (FM and JR) independently conducted the
quality assessment of the studies in an unblinded fashion
using the Newcastle-Ottawa quality assessment scale
(Additional file 1) [13]. Points were awarded to observa-
tional studies for comparability if they controlled or ad-
justed for age, sex, and cardiovascular disease, such as
hypercholesterolemia, hypertension, diabetes, coronary
heart disease, atrial fibrillation, peripheral vascular disease,
carotid stenosis, valvular heart disease, heart failure,
chronic rheumatic heart disease, as these are considered
important risk factors for stroke. Self-controlled case-
series studies were scored with the cohort studies, how-
ever we interpreted ‘cohort representativeness’ as how rep-
resentative the selected cases were of patients with stroke
in the community. Discrepancies were resolved through
discussion with another author (KR).
Statistical analysis
As risk of stroke varied with time since herpes zoster in-
fection we pooled adjusted relative risks (RR) reported
for similar follow-up durations (e.g. first 1 month,
3 months, 1 year and beyond 1 year since herpes zoster
infection, where possible) across studies separately using
random-effects inverse variance models. We also per-
formed subgroup analyses by patients older and younger
than approximately 40 years where possible. We chose
this cut-off as most studies reported stroke risk stratified
by age less than and greater than 40 years. Unfortu-
nately, there were not enough studies reporting results
in the over 65 year age group to combine these findings.
We measured heterogeneity across studies using the I2
statistic, with higher values reflecting increasing hetero-
geneity. We assessed sources of heterogeneity by sub-
group analysis and publication bias by examining funnel
plots. Stata version 12.1 (StataCorp, College Station, TX)
was used for analysis. Statistical tests were two sided
with p < 0.05 defining statistical significance.
Results
Search results and study characteristics
Figure 1 identifies the search results and selection process.
Of the 4478 articles identified through the database search
1038 were removed due to duplicates and 46 articles were
reviews of literature with topics such as pathophysiology
and clinical features as well as treatment of herpes zoster,
and 3100 articles were considered as irrelevant leaving
294 articles which were reviewed in detail by two individ-
uals. Articles were deemed irrelevant if they didn’t meet
the inclusion criteria, i.e. examined varicella or chickenpox
instead of shingles, examined encephalitis instead of
stroke with zoster, examined children primarily, examined
herpes simplex instead of varicella zoster, examined vac-
cination, considered irrelevant outcomes (i.e. biomarker
studies, cognitive impairment, stress). Of the 294 articles
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considered for a detailed review, the majority considered
an irrelevant topic, while some were cases studies, non-
English, or duplicates. This left 12 studies for inclusion in
the review, nine studies with a full published manuscript
[14–22] and 3 abstracts. Since the necessary results from
the abstracts were unavailable and investigators declined
to provide us with these when contacted, all 3 abstracts
were excluded from analysis, leaving 9 studies for inclu-
sion in our meta-analysis.
The characteristics of the 9 studies included in the
meta-analysis are displayed in Table 1. Two of the earli-
est studies used the Taiwanese National Health Insur-
ance Research Database (NHIRD) [15, 17]. Both Breur et
al. [14] and Langan et al. [16] used the United King-
dom’s Clinical Practice Research Datalink (CPRD) and
The Health Improvement Network (THIN) general prac-
tice databases respectively. The European studies con-
ducted by Sreenivasan et al. [21] and Sundstrom et al.
[19] used the Danish and Swedish registries, respectively.
The two USA-based studies used Medicare [18] and
Olmsted County residents, [20] respectively and the lat-
est study used the Korean Health Insurance database
[22]. Two studies performed a self-controlled case series
analyses, [16, 18] while the other seven are retrospective
cohort in design [14, 15, 17, 19–22]. Follow-up time var-
ied from 1 to 24 years, but most studies reported the
risk over various time periods post zoster infection.
All studies adjusted for age and sex. All studies except
Sundström et al. [19] adjusted for major cardiovascular
risk factors such as hypertension diabetes, congestive
heart failure, dyslipidemia, ischemic heart disease, atrial
fibrillation, intermittent arterial claudication, carotid
stenosis, and valvular heart disease. Only the study by
Breuer et al. [14] was able to adjust for smoking and
obesity (also considered as cardiovascular risk factors).
However the two studies by Minassian [18] and Langan
[16] also provided strong control for confounding by using
a self-controlled case-series design which only makes
within-person comparisons. Antiviral therapy varied be-
tween studies with two studies including cases that were
all taking antivirals, [18, 21] while Langan [16] and Lin
[17] reported that 55% and 24% of their patients receiving
antiviral therapy respectively. The mean age of the partici-
pants in each study ranged from 47 to 80 years. Langan et
al. [16], Minassian et al. [18], and Yawn et al. [20] included
the oldest participants with mean ages of 77 (median), 69,
and 80 years, respectively. The proportion of women was
higher than men in most of the studies.
Four studies examined the combined outcome of stroke
or TIA, [15, 17, 21, 22] whereas the other five studies ex-
amined the risk of stroke only [14, 16, 18–20]. All studies
examined stroke risk following zoster except Lin et al. [17]
who examined stroke risk after herpes zoster ophthalmi-
cus only. An additional four studies also included an ana-
lysis of stroke risk following ophthalmicus [14–17, 22].
Sreenivasan et al. [21] used acyclovir prescriptions filled in
a certain strength and quantity to identify cases of HZ but
used ICD10 codes to identify incident stroke and TIA.
The rest of the studies used diagnosis codes to identify
their HZ cases and cerebrovascular events.
Risk of bias
Assessment of study validity using the Newcastle-Ottawa
Scale revealed a low risk of bias amongst studies (Additional
file 1: Table S1). Among the nine studies three scored a full
9/9, five studies scored 8/9, and one study scored 6/9.
Herpes zoster infection and risk of stroke
Our meta-analysis indicates an elevated risk of stroke after
zoster (Fig. 2). The risk of stroke was greatest during the
Fig. 1 Study selection for inclusion into the meta-analysis
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first month following the HZ episode RR 1.78 (95% CI:
1.70-1.88 I2 = 0%), dropping to 1.43 (95% CI: 1.38-1.47, I2
= 0%) over the first 3 months following HZ, to 1.20 (95%
CI: 1.14–1.26, I2 = 55%) in the first year after the HZ epi-
sode, and finally to 1.07 (95% CI: 0.99–1.15, I2 = 91%) over
3 or more years. For the studies with one year follow-up,
the considerable heterogeneity was due to the smaller ef-
fect size reported by Minassian et al. [18]. This could be
due to the self-controlled case-series design, the relatively
older age of the patients and the specific outcome of is-
chemic stroke. For the studies with three or more years of
follow-up, heterogeneity was introduced by the larger ef-
fect size reported by Kwon et al. [22]. This may reflect dif-
ferences in the study population in the South Korean
study or study design, such as misclassification of the TIA
diagnosis. We did not find evidence of publication bias,
however there were few studies.
The risk of stroke following herpes zoster ophthalmi-
cus appeared stronger compared to an episode of HZ
only (1 month: RR 2.05 95% CI: 1.82-2.31, I2 = 0%) as
seen in Fig. 3. The risk also remains high in the first year
after the HZ episode (RR 2.26, 95% CI: 1.35–3.78), but
there was considerable heterogeneity (I2 = 91%). This
heterogeneity may be explained by the Langan et al. [16]
and Minnassian et al. [18] studies using a self-controlled
case series design, thus potentially having better con-
founding control than the other two cohort studies [15,
17]. Kang et al. [15] and Lin et al. [17] likely produced
similar effect estimates as their data was ascertained
from the same Taiwanese Health Insurance database, al-
beit in different patients over different time periods. Fi-
nally, the Breuer et al. [14] study found no excess risk
over 24 years of follow-up.
Figure 4 details stroke risk after HZ in different age
groups. In younger adults (less than 40 years) there is a sig-
nificant increased risk of stroke within a year after zoster
episode (RR 2.96, 95% CI: 1.05-8.41, I2= 86%), but signifi-
cant heterogeneity in these results. The larger effect size by
Sundstrom et al. [19] could be due to not adjusting for any
confounders beyond age and sex. The study cohort by Sree-
nivasan and colleagues [21] differed by being based on a
treated population as they used use of antivirals as a proxy
for identifying their HZ cases. For the younger aged cohort,
the risk remains significant in the long-term, that is beyond
11 years after the acute HZ episode (RR 1.39, 95% CI: 1.27–
1.52, I2= 0%). More studies evaluated stroke risk in older co-
horts, and like the younger cohorts, we found that older
adults also demonstrate a significant increase in stroke risk
one year after zoster (RR 1.19, 95% CI: 1.13–1.24, I2= 44%),
with this risk being greatest shortly after the acute zoster in-
fection. The risk remains elevated beyond 3 years of follow
up (RR 1.09, 95% CI: 1.01–1.17, I2= 86%), but with consider-
able heterogeneity in the results in line with the overall re-
sults where Kwon et al. [22] reported a greater effect size.
Discussion
This is the first study to systematically review and per-
form a meta-analysis of the risk of stroke following a
NOTE: Weights are from random effects analysis
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Langan et al 2014
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Yawn et al 2016
Subtotal  (I-squared = 90.8%, p = 0.000)
Study
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1.05 (1.02, 1.09)
1.02 (0.86, 1.21)
1.07 (0.99, 1.15)
ES (95% CI)
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100.00
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0.65
100.00
5.56
21.81
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29.77
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Fig. 2 Effect of herpes zoster on stroke risk by length of study follow-up
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zoster infection. We found an elevated risk of stroke
after pooling the results of nine observational studies.
The risk was greatest shortly after the acute zoster epi-
sode but diminished slowly over time, although the risk
was still significant after the first year. The risk of stroke
was more pronounced in patients with herpes zoster
ophthalmicus infection.
Varicella zoster virus is a highly neurotropic DNA
virus that infects more than 95% of the world population
[1]. Varicella infection or chickenpox most commonly
occurs in children after which viral latency is established
whereby the virus resides, but remains dormant, in the
cranial nerve, dorsal root, and autonomic ganglionic
neurons. During latency, varicella zoster virus transcrip-
tion is limited and without production of virions. The
increased stroke risk after reactivation of the varicella
zoster virus may be due to the vasculopathy characteris-
tically caused by this pathogen [23, 24]. By looking at
brain tissue of individuals who have died from varicella
infection, investigators believe the virus migrates trans-
axonally from the trigeminal nerves to cranial vascula-
ture and spreads transmurally through the tunica
adventitia, media, and intima, causing inflammation and
thickening of the intima, reducing the media, and dam-
aging the inner elastic layer of the vessels [24]. The pres-
ence of varicella zoster virus in intracerebral arteries is
seen shortly after the acute infection and as late as
10 months after, allowing for the possibility that the risk
of stroke could be present for up to a year after the ini-
tial HZ infection [25, 26].
The second possible mechanism is related to inflamma-
tion associated with systemic infection that can create a
state in which the blood is more prone to clotting. Release
of cytokines such as TNF-alpha and interleukin-2 during
inflammation or stress leads to endothelial dysfunction
disruption of atheromatous plaques and hypercoagulabil-
ity, all leading to acceleration of atherosclerosis [27, 28]. A
number of studies have suggested microbes play some role
in inflammation, thereby accelerating atherosclerosis [29].
For example, Wang et al. conducted a meta-analysis that
showed Helicobacter pylori infection contributes to risk of
ischemic stroke,[30] however a more recent analysis re-
futed this [31]. In their meta-analysis, Chen et al. found an
increased risk of cerebrovascular disease with the presence
of IgG for Chlamydia pneumonia [32]. In a self-controlled
case-series of over 50,000 patients, Smeeth et al., demon-
strated a relationship between recent respiratory tract in-
fection and myocardial infection (IR 4.95, 95%CI: 4.43–
5.53) as well as stroke (IR 3.19, 95%CI: 2.81–3.62) [33].
The risks for both events were highest in the first 3 days,
then gradually decreased to baseline the weeks following
the acute infection.
We found evidence that the risk of stroke was present
in both younger and older individuals but was more pro-
nounced in the younger patients. However, this analysis
was limited by only four studies that had one year follow-
up data in patients less than 40 years of age, [15, 19, 21]
and the results were considerably heterogeneous. One rea-
son for this discrepancy could be that Sundstrom et al.
[19] did not adjust for any confounders beyond age and
NOTE: Weights are from random effects analysis
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Fig. 3 Effect of herpes zoster ophthalmicus on stroke risk by length of study follow-up
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sex and given that comorbidies would play a role in zoster
incidence in the younger population, their results should
be interpreted with caution. Further, in the younger popu-
lation many risk factors may not be recorded or reported
by patients and therefore despite adjustment, residual con-
founding may still be present. We were able to pool six
studies to evaluate stroke risk in older patients one year
after the acute HZ episode, giving less heterogeneous
results. Despite differences in study populations, the stud-
ies were consistent in the magnitude of the risk being
around 20% higher within the first year post HZ.
We observed a greater than 2-fold increase in stroke
risk in the first year following herpes zoster ophthalmicus
or zoster with trigeminal nerve involvement which as with
general HZ decreased over time. The increased risk was
not surprising given that HZO arises when latent VZV
NOTE: Weights are from random effects analysis
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Fig. 4 a Effect of herpes zoster on stroke risk by length of study follow-up and age (younger adults, aged 40 years or less). b Effect of herpes zos-
ter on stroke risk by length of study follow-up and age (older adults, aged >40 years)
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infection of the trigeminal ganglion becomes reactivated
and involves the ophthalmic division of the trigeminal
nerve, giving rise to a number of head and neck-related
complications, including stroke or TIA [9, 26].
The pathogenesis behind increased stroke risk could
also lead to increased risk for a myocardial infarction
(MI). In our meta-analysis we did not address this risk
and only two studies examined this outcome. Using a
retrospective cohort of 106,601 HZ cases and 213,202
controls matched on age, sex, and general practice from a
UK general practice database, Breuer et al. examined the
risks of MI [14]. They found an increased risk overall (HR
1.10), but more pronounced in those less than 40 years of
age (HR 1.49). Yawn et al. evaluated MI risk in 4,454 indi-
viduals with herpes zoster and 16,740 individuals without
herpes zoster, all with no history of prior MI before their
index date [20]. They found a greater risk of MI at
3 months post HZ (HR 1.68), but this reduced over time
to a non-significant findings at 3 years (HR = 1.17). We
agree with the authors of the two studies, that there is
need for more studies to be conducted using large datasets
to further examine the causal association.
There were too few studies for us to be able to exam-
ine stroke risk according to gender however the three
studies that provided their results stratified by sex, found
no differences in risk for men or women [15, 19, 20].
Clinical trials show that antivirals hasten the resolution
of lesions, reduce the formation of new lesions and viral
shedding as long as they are taken within 72 h after the
onset of the rash [1]. The greatest benefit for these
agents are in those at greatest risk for complications
such those aged 50 years or older, have moderate to se-
vere rash and/or pain, involvement of the face or eye, or
are immunocompromised due to medications or disease.
Unfortunately, there were too few studies for us to be
able to examine stroke risk according to receipt of anti-
viral therapy, however, this would be an important piece
of information as provision of antiviral therapy by clini-
cians may be of use for those adults with a high cardio-
vascular risk after zoster infection; further research is
warranted on this topic. Similarly only one study exam-
ined the effect of vaccination on stroke risk after zoster,
but had insufficient numbers of patients vaccinated in
order to demonstrate a significant difference in stroke
risk [18]. However, other studies have demonstrated that
vaccination does reduce HZ incidence, hence they
should be recommended for individuals at high vascular
risk or with significant comorbidities [34]. Our findings
focus solely on results from observational studies, al-
though we acknowledge that randomized controlled tri-
als would not be ethically possible in this setting.
Observational studies are limited by their lack of
randomization and inherent risk of bias. However, all
nine studies were rated as having a low risk of bias and
adjusted for important confounders such as demograph-
ics and a range of cardiovascular risk factors. Two stud-
ies implemented a self-controlled case series design,
which potentially gives even stronger confounding con-
trol [16, 18]. However, we cannot rule out the possibility
of some residual confounding due to stress, mental
health or life events. The study by Sundström [19] had a
greater risk of bias due to its primary aim being to assess
HZ incidence, hence the recording of methods used to
assess stroke risk were limited.
Our study is not without limitations. Occasionally we ob-
served heterogeneity amongst studies results potentially
due to different study designs, as previously mentioned. All
of the studies except Yawn et al. [20], relied on electronic
medical records to ascertain both the HZ and the stroke
outcome. Administrative data has been reported to over-
estimate herpes zoster by 10–15%, [35] but other studies
did make attempts to reduce HZ miscoding, by for ex-
ample, excluding recurrent HZ, which may be confused
with herpes simplex [14] or requiring concurrent antiviral
therapy [18]. Regarding the accuracy of stroke recording, in
a study of the UK databases nearly 90% of patients with
stroke had diagnoses confirmed in their written medical
record [36]. Studies varied as to whether their stroke defin-
ition included TIA or not, and those including TIA would
have potentially overestimated risk as TIA is more common
than stroke [14]. 10 or READ/10 or READ codes to identify
zoster cases, study outcomes and confounders, except Yawn
et al., [20] who used medical records, and Sreenivasan et
al., [21] who used antivirals as a proxy of zoster infection.
Given that the use of antivirals as surrogate for zoster infec-
tion has not been validated, we performed a sensitivity ana-
lysis and excluded this study from our analyses; however it
did not change our results.
Conclusions
Stroke risk is significantly increased shortly after acute
zoster infection and remains elevated for up to one year.
Herpes zoster ophthalmicus increases stroke risk by a
larger magnitude. Increased efforts should be made to
provide vaccinations to at-risk individuals, especially
those with a high cardiovascular risk.
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